Inhibition of platelet aggregation in baboons: Therapeutic implications for xenotransplantation

Xenotransplantation

Volumn 7, Issue 4, 2000, Pages 247-257

  Alwayn, Ian P J ^a   Appel III, James Z ^a   Goepfert, Christian ^b   Buhler, Leo ^a   Cooper, David K C ^a   Robson, Simon C ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Baboons; Coagulation; Eptifibatide; Platelet aggregation; Rejection; Xenotransplantation

Indexed keywords

1 BENZYLIMIDAZOLE; AURINTRICARBOXYLIC ACID; EPTIFIBATIDE; FIBRINOGEN; FUCOIDIN; HEPARIN; NICOTINAMIDE; NITROPRUSSIDE SODIUM; PROSTACYCLIN DERIVATIVE; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; GRAFT OCCLUSION; GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; XENOTRANSPLANTATION;

ANIMALS; ANTICOAGULANTS; AURINTRICARBOXYLIC ACID; BLOOD COAGULATION; BLOOD PLATELETS; EPOPROSTENOL; HEPARIN; PAPIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; THROMBOXANE A2; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033789432     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.2000.00965.x     Document Type: Article

References (62)

1. Experimental renal heterotransplantation. I. In widely divergent species
2. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon
3. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy
4. Transplantation of discordant xenografts: A challenge revisited
5. Barriers to xenotransplantation
6. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates
7. Immunobiology of delayed xenograft rejection
8. Relationship of platelets, blood coagulation, and fibrinolysis to hyperacute rejection of renal xenografts
9. Factors in xenograft rejection
10. Activation of human platelets by the membrane-expressed Al domain of von Willebrand factor
11. Xenogeneic endothelial cells activate human prothrombin
12. Apyrase administration prolongs discordant xenograft survival
13. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model
14. Intravenous synthetic alphaGal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation
15. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts
16. Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption
17. Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates
18. Porcine hematopoietic cell transplantation in nonhuman primates is complicated by thrombotic microangiopathy
19. Prolongation of renal xenografts by the simultaneous sequestration of preformed antibody, inhibition of complement, coagulation and antibody synthesis
20. Platelet trapping by sheep kidney and heart xenografts in the dog
21. Modification of the vascular lesions of rejection in cadaveric renal allografts by dipridamole and anticoagulants
22. Thrombin inhibition in discordant xenotransplantation
23. Pathogenesis of atherosclerosis: Special pathogenetic factors-inflammation and immunity: Platelets
24. Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis
25. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo
26. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster
27. Inhibition of the generation of thrombin and factor Xa by a fucoidan from the brown seaweed Ecklonia kurome
28. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutanaous route
29. Thrombin promotes platelet-mediated melanoma cell adhesion to endothelial cells under flow conditions: Role of platelet glycoproteins P-selectin and GPIIb-IIIa
30. Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs
31. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2
32. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation
33. Effect of thromboxane synthase inhibition on eicosanoid levels and blood flow in ischemic rat brain
34. Rationale for antiplatelet therapy in patients with atherothrombotic disease
35. Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis
36. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis
37. New antithrombotic agents for the prevention and treatment of deep vein thrombosis
38. Regulation of thrombosis and hemostasis by antithrombin
39. Multifunctional roles of thrombin
40. How the protease thrombin talks to cells
41. Nitric oxide and the vascular endothelium in myocardial ischaemia-reperfusion injury
42. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis
43. Nitric oxide: Physiology, pathophysiology, and pharmacology
44. Differential effects of N-acetylcysteine on nitroglycerin- and nicorandil-induced vasodilation in human coronary circulation
45. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiba, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
46. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
47. Endothelial cell activation and thromboregulation during xenograft rejection
48. Platelet activation and interactions with the microvasculature
49. Thromboregulation: Multicellular modulation of platelet reactivity in hemostasis and thrombosis
50. Regulation of platelet anchorage and signaling by integrin alpha IIb beta 3
51. The platelet membrane glycoprotein IIb/IIIa complex. Structure, function, and relationship to adhesive protein receptors in nucleated cells
52. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets
53. Thromboxane mediates pulmonary vasoconstriction and contributes to cytotoxicity in pig lungs perfused with fresh human blood
54. Prostacyclin is a key mediator of the vasodilator action of dopamine in humans
55. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
56. Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans
57. Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin
58. Potentiation of Cl inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection
59. Nitric Oxide. III. A molecular prelude to intestinal inflammation
60. Exogenous NO enhances hydrogen peroxide-mediated neutrophil adherence to cultured endothelial cells
61. Inhibition of platelet aggregation by the GPIIb/IIIa antagonist reopro does not significantly prolong xenograft survival in an ex vivo model
62. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells